May 02, 2016
2 min watch
Save

VIDEO: Luminate meets primary endpoint in phase 2 study for vitreomacular traction

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

SEATTLE — At the Association for Research in Vision and Ophthalmology meeting, Baruch D. Kuppermann, MD, discusses results of the phase 2 study of Allegro’s Luminate for the treatment of vitreomacular traction.